Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Humacyte, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Humacyte Second Quarter 2023 Financial Results and Business Update"
07/26/2023 8-K Quarterly results
06/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/26/2023 SC 13D/A Niklason Laura E reports a 17.9% stake in HUMACYTE, INC.
05/25/2023 144 Form 144 - Report of proposed sale of securities:
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "Humacyte First Quarter 2023 Financial Results and Business Update"
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/24/2023 10-K Annual Report for the period ended December 31, 2022
03/24/2023 8-K Quarterly results
Docs: "Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update"
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
12/12/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BY LAWS OF"
09/20/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Humacyte Expands Board of Directors and Leadership Team with New Appointments"
09/19/2022 SC 13D/A Niklason Laura E reports a 21.3% stake in HUMACYTE, INC.
09/15/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/12/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
09/12/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/12/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/09/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/09/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/01/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
09/01/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/12/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 8-K Quarterly results
Docs: "Humacyte Second Quarter 2022 Financial Results and Business Update"
06/13/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/13/2022 8-K Quarterly results
05/13/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy